- Conditions
- Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
- Interventions
- Certolizumab pegol, Placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 925
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Plaque Psoriasis
- Interventions
- apremilast
- Drug
- Lead sponsor
- Psoriasis Treatment Center of Central New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- East Windsor, New Jersey
- Conditions
- Nail Psoriasis
- Interventions
- Methotrexate, Triamcinolone Acetonide 10mg/mL, Saline
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
- Interventions
- Resource sheets, Community Resource Specialist, Nurse Navigator
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Plaque Psoriasis
- Interventions
- Deucravacitinib, Ustekinumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 3,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 101 more
- Conditions
- Psoriasis
- Interventions
- UV-B Lightsource and Fiber Optic Comb
- Device
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psoriasis
- Interventions
- M518101, Vehicle
- Drug
- Lead sponsor
- Maruho North America Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Phoenix, Arizona • San Diego, California + 27 more
- Conditions
- Psoriasis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Rochester, New York
- Conditions
- Psoriasis Vulgaris
- Interventions
- Tildrakizumab Prefilled Syringe
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Psoriasis Guttate, Plaque Psoriasis
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Plaque Psoriasis
- Interventions
- 122-0551 Foam, Vehicle Foam
- Drug
- Lead sponsor
- Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Fremont, California • Miami, Florida • Arlington Heights, Illinois + 5 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Bimekizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 20
- States / cities
- Boise, Idaho • Lexington, Kentucky • Baton Rouge, Louisiana + 17 more
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Midazolam, AIN457
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 5 more
- Conditions
- Moderate-to-severe Chronic Plaque Psoriasis
- Interventions
- Tildrakizumab, Placebo, Etanercept
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 6 Years to 215 Months
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 5
- States / cities
- Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more
- Conditions
- Rheumatic Joint Disease
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
- Conditions
- Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Psoriasis Vulgaris, Psoriasis
- Interventions
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 29
- States / cities
- Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Not listed
- Lead sponsor
- Groupe Hospitalier Pitie-Salpetriere
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cleveland, Ohio
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Interventions
- Infliximab (Remicade)
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,971 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
- Conditions
- Psoriasis
- Interventions
- BMS-986322, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Encino, California • Fountain Valley, California + 15 more
- Conditions
- Plaque Psoriasis, Scalp Psoriasis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more
- Conditions
- Plaque Psoriasis
- Interventions
- 188-0551 Spray, Vehicle Spray
- Drug
- Lead sponsor
- Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more
- Conditions
- Plaque Psoriasis
- Interventions
- TAK-279
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,099 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Moderate-to-severe Chronic Plaque Psoriasis
- Interventions
- Ponesimod
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Glendale, Arizona • Fremont, California • Miami, Florida + 7 more